Skip to content

Peptide Therapy

Peptides for Growth Hormone Support

People look at growth-hormone support peptides when they want sharper recovery, deeper sleep, more lean mass, body-composition change, training resilience, or a more youthful sense of repair. The practical entry point is the growth-hormone axis itself. These protocols nudge the body's own growth-hormone pulses and raise downstream markers like insulin-like growth factor 1.

Reading time
5 min
Source last reviewed
12 May 2026
Last updated
12 May 2026

Reader compass

What to sort first

01

The reason for support

Recovery, sleep, body composition, deficiency care, and age-related decline are different reasons to target this pathway.

02

The pathway being used

Sermorelin, CJC-1295, ipamorelin, and oral secretagogues act through related but different growth-hormone signals.

03

The monitoring plan

IGF-1, glucose, symptoms, sleep, edema, and body-composition markers help show whether the protocol fits.

The appeal makes sense. Growth hormone is wired into repair, sleep architecture, body composition, connective tissue, and the felt sense that the body can bounce back from hard work.

In longevity clinics, the framing is usually about encouraging the body's own signaling rather than taking recombinant human growth hormone directly.

IGF-1 stands for insulin-like growth factor 1, one of the main blood markers used to read downstream growth-hormone activity. It is not a longevity score.

It is a way to see whether a protocol is moving the biology it claims to move.

The main growth-hormone peptide categories

Protocols here sort into a few categories.

Decision table 01
CategoryCommon examplesWhat people are usually pursuing
Growth-hormone releasing hormone analogsSermorelin, CJC-1295.A signal upstream of pituitary growth-hormone release.
Growth-hormone secretagoguesIpamorelin and related secretagogues.A pulse-like growth-hormone release signal, often paired with GHRH analogs.
Oral ghrelin mimeticsMK-677, also called ibutamoren.Oral stimulation of growth-hormone and IGF-1 signaling.
Medical growth-hormone therapyRecombinant human growth hormone.Deficiency treatment under clinical endocrine care, not a peptide-support protocol.
Combination clinic protocolsCJC-1295 plus ipamorelin, sermorelin-based plans, layered recovery protocols.Recovery, sleep, lean mass, and body-composition support with monitoring.

GHRH stands for growth-hormone releasing hormone. GHS stands for growth-hormone secretagogue. One category sends a releasing-hormone-style signal. Another sends a secretagogue-style signal.

Clinics often combine the two to create a stronger or more sustained effect on the axis.

What the experience looks like

Most clinic-led plans involve injections on a set schedule, often at night, because growth hormone naturally pulses during sleep. Oral MK-677 sits a little apart from that pattern.

It is not injected and is not technically a peptide, but it lives in the same conversation often enough that it belongs alongside the rest.

A real plan should include:

  • baseline symptoms and goals;
  • IGF-1 and relevant metabolic labs;
  • sleep, training, body-composition, and recovery context;
  • the exact peptide, pharmacy source, schedule, and route;
  • side-effect plan;
  • follow-up labs;
  • a decision point for continuing, changing, or stopping.

What someone might notice

Most people are after deeper sleep, easier recovery, better training tolerance, body-composition change, or less soreness between sessions.

Some also pay attention to skin, hair, connective tissue, or a general sense of vitality.

Those are reasonable reasons to be curious. They still need tracking.

Sleep quality, training logs, waist, weight, DEXA, strength, soreness, glucose markers, and symptoms turn a fuzzy "anti-aging" promise into something measurable.

Where the evidence fits

Growth-hormone secretagogues can raise growth-hormone and IGF-1 signaling.

A review of the class describes possible relevance to appetite, lean mass, wasting states, obesity, bone turnover, sleep, and quality of life, while emphasizing safety and careful patient selection 1.

CJC-1295 has human pharmacology data behind it.

In a clinical study, CJC-1295 raised growth hormone and IGF-1 for several days after dosing and was evaluated for safety and pharmacodynamic effects as a long-acting GHRH analog 2.

Other work reported preserved pulsatile growth-hormone secretion alongside higher trough and mean growth-hormone and IGF-1 levels 3.

MK-677 has been studied in older adults. Shorter trials showed increased growth-hormone and IGF-1 signaling.

A longer trial in older adults found increases in fat-free mass but did not show the same clarity for strength or physical function 4 5.

That pattern matters. The pathway can move. The real-life meaning comes from the person, dose, duration, baseline, and outcome being measured.

Decision table 02
ClaimEvidence statusHow to read it
Raise IGF-1Established (for some agents)A pathway change, not a complete outcome.
Improve lean massEmerging (by agent and population)Pair with DEXA, strength, protein, and training context.
Improve sleep or recoveryEmerging / DebatedTrack sleep, training, soreness, and daily function.
Support longevityEarly stageGrowth-hormone-axis movement is not yet proof of lifespan benefit.
Improve physical functionDebatedHuman studies do not always translate biology into function.

How to make the protocol useful

A strong protocol starts with a specific target and a monitoring plan. "I want better recovery" is a starting line, not a finish line.

It needs to translate into deeper sleep continuity, higher training volume, fewer missed sessions, faster bounce-back from hard sessions, or measurable body-composition change with stable glucose.

  1. Define the job

    Sleep, recovery, body composition, deficiency care, and vitality need different expectations.

  2. Measure the axis

    IGF-1 and metabolic labs help show whether the protocol is moving the intended pathway safely.

  3. Track the lived result

    Use sleep data, training logs, symptoms, strength, waist, and DEXA when body composition matters.

  4. Adjust around side effects

    Fluid retention, joint symptoms, appetite, glucose changes, and sleep shifts should change the plan.

Safety and fit

Growth-hormone-axis protocols can affect fluid retention, joint or nerve symptoms, carpal-tunnel-like symptoms, appetite, glucose, insulin resistance, edema, headaches, sleep, and IGF-1.

They are not a fit for people with active cancer, a history of certain cancers, uncontrolled diabetes, severe insulin resistance, significant edema, untreated sleep apnea, complex endocrine disease, or layered medication regimens without clinician oversight.

Source quality matters here, because most products in this category are injectable.

A good provider can explain the exact compound, where it comes from, how it is used, what response is expected, what side effects matter, and when to stop.

Where growth-hormone peptides fit in a longevity plan

Growth-hormone support sits inside a bigger recovery and body-composition strategy.

It should not stand in for resistance training, protein, sleep, glucose control, body-composition tracking, or a proper endocrine workup when one is called for.

Peptides for muscle growth and body composition covers body-composition goals in more detail.

Testosterone replacement therapy, menopause hormone therapy, and thyroid optimization cover adjacent endocrine decisions.

DEXA body composition is the companion test when lean mass and fat mass are part of the goal.

A good growth-hormone-support protocol is measured, not mystical.

Name the reason for using it, track the pathway, track the lived result, and adjust the plan when the biology or the side effects tell you to.

Sources and references
  1. 1

    Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews. 2018. PMC ↑

  2. 2

    Teichman SL, et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295." The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed ↑

  3. 3

    Ionescu M, et al. "Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295." The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed ↑

  4. 4

    Chapman IM, et al. "Stimulation of the growth hormone-insulin-like growth factor I axis by daily oral administration of MK-677 in healthy elderly subjects." The Journal of Clinical Endocrinology & Metabolism. 1996. PubMed ↑

  5. 5

    Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine. 2008. PMC ↑

  6. 6

    U.S. Food and Drug Administration. Federal Register notice on sermorelin acetate injection not withdrawn from sale for reasons of safety or effectiveness (78 FR 14095). 2013. Federal Register ↑

  7. 7

    U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Updated May 14, 2026. Accessed September 2026. FDA ↑

  8. 8

    U.S. Food and Drug Administration. "Tesamorelin for injection, full prescribing information." 2025. FDA ↑

  9. 9

    World Anti-Doping Agency. "The Prohibited List." 2026. Accessed September 2026. WADA ↑

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint